NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36668
Issuer: Dermira, Inc.
Exchange: The Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 2055 Woodside Road
Redwood City,
CALIFORNIA
94061
Telephone number: 650-421-7207
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
o 17 CFR 240.12d2-2(a)(2)
x 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, The Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2020-02-20ByO'Neil BlakeSenior Specialist
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Journey Medical Charts.
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Journey Medical Charts.

Dermira, Inc. News

Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
Thursday 2 May 2024 (5 days ago) • GlobeNewswire Inc.
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
Thursday 25 April 2024 (2 weeks ago) • GlobeNewswire Inc.
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Friday 22 March 2024 (2 months ago) • GlobeNewswire Inc.
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Monday 18 March 2024 (2 months ago) • GlobeNewswire Inc.
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Friday 15 March 2024 (2 months ago) • GlobeNewswire Inc.
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
Wednesday 13 March 2024 (2 months ago) • GlobeNewswire Inc.
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Saturday 24 February 2024 (2 months ago) • Edgar (US Regulatory)
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Saturday 6 January 2024 (4 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Wednesday 3 January 2024 (4 months ago) • Edgar (US Regulatory)
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Wednesday 3 January 2024 (4 months ago) • GlobeNewswire Inc.
Form S-8 - Securities to be offered to employees in employee benefit plans
Saturday 16 December 2023 (5 months ago) • Edgar (US Regulatory)

More Dermira, Inc. News Articles